• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Knape Noel

    4/26/24 3:28:17 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care
    Get the next $MGRM alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Knape Noel

    (Last) (First) (Middle)
    3913 TODD LANE

    (Street)
    AUSTIN TX 78744

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    MONOGRAM ORTHOPAEDICS INC [ MGRM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    04/24/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option $2.33 04/24/2024 A 25,000(1) (2) 04/24/2024 Common Stock 25,000 $0.00 75,000 D
    Explanation of Responses:
    1. The options were issued under the Company's 2019 Stock Option and Grant Plan.
    2. 25% of the shares of Common Stock underlying the options will vest on the 1-year anniversary of the date of grant, and the remaining 75% of such shares shall vest in 12 equal 6-month installments over the next six years, becoming fully vested on April 24, 2030 (provided that Mr. Knape continues to have a service relationship with the Company as of the date of each vesting described herein).
    /s/ Noel Knape 04/26/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MGRM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MGRM

    DatePrice TargetRatingAnalyst
    12/9/2024$4.00Buy
    ROTH MKM
    More analyst ratings

    $MGRM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Monogram Technologies Reports First Quarter 2025 Financial Results

      Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World's First Autonomous Saw-Based Robotic TKA Surgeries on Live Patients Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the first quarter ended March 31, 2025. First Quarter 2025 and Subsequent Operational Highlights The U.S. Food and Drug Administration ("FDA") granted 510(k)

      5/14/25 4:01:00 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • Monogram Technologies Provides 510(k) Submission Update Following Positive Meeting with FDA

      Management Anticipates That it has Sufficiently Addressed the FDA's Concerns to Mitigate the Need for a Clinical Data RequestManagement Anticipates a Comprehensive AIR Response in Q1 2025 AUSTIN, TEXAS / ACCESSWIRE / December 18, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update from its Submission Issue Request (SIR) meeting with the U.S. Food and Drug Administration ("FDA") on December 17, 2024, regarding its 510(k) premarket filing submission for the Company's mBôs TKA System (the "Application").The Application was submitted on

      12/18/24 8:31:00 AM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • Monogram Technologies Announces Management and Related Parties Complete Open Market Purchases of MGRM Common Stock Totaling $1 Million

      AUSTIN, TEXAS / ACCESSWIRE / December 2, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced completed purchases of MGRM common stock on the open market by certain related parties including Chief Financial Officer Noel Knape, totaling approximately $1 million. Additional details can be found on the Form 8-K filed today by the Company under Item 8.01 Other Events."Our senior management team has purchased shares in the open market, reflecting high confidence in our strategy and expectation to create long-term shareholder value," said Ben Sexson

      12/2/24 4:05:00 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care

    $MGRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Knape Noel was granted 288,461 shares (SEC Form 4)

      4 - Monogram Technologies Inc. (0001769759) (Issuer)

      11/26/24 8:52:37 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Knape Noel

      4 - MONOGRAM ORTHOPAEDICS INC (0001769759) (Issuer)

      4/26/24 3:28:17 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care

    $MGRM
    SEC Filings

    See more
    • SEC Form 10-Q filed by Monogram Technologies Inc.

      10-Q - Monogram Technologies Inc. (0001769759) (Filer)

      5/14/25 3:59:51 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • Monogram Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Monogram Technologies Inc. (0001769759) (Filer)

      4/29/25 6:05:28 AM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by Monogram Technologies Inc.

      S-8 - Monogram Technologies Inc. (0001769759) (Filer)

      4/17/25 3:12:04 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care

    $MGRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Monogram Technologies with a new price target

      ROTH MKM initiated coverage of Monogram Technologies with a rating of Buy and set a new price target of $4.00

      12/9/24 7:59:36 AM ET
      $MGRM
      Medical/Dental Instruments
      Health Care

    $MGRM
    Financials

    Live finance-specific insights

    See more
    • Monogram Technologies Reports First Quarter 2025 Financial Results

      Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World's First Autonomous Saw-Based Robotic TKA Surgeries on Live Patients Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the first quarter ended March 31, 2025. First Quarter 2025 and Subsequent Operational Highlights The U.S. Food and Drug Administration ("FDA") granted 510(k)

      5/14/25 4:01:00 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • Monogram Technologies to Host Third Quarter 2024 Results Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time

      AUSTIN, TX / ACCESSWIRE / November 12, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the third quarter ended September 30, 2024 and to discuss key milestones. A press release detailing these results will be issued prior to the call.Monogram CEO Ben Sexson and CFO Noel Knape will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can b

      11/12/24 8:31:00 AM ET
      $MGRM
      Medical/Dental Instruments
      Health Care
    • Monogram Technologies Announces Preferred Stock Dividends

      AUSTIN, TX / ACCESSWIRE / October 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, announced today the declaration of a dividend of $0.0255 per share payable to holders of record of shares of the Company's 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") at the close of business on October 1, 2024. In addition, the Company announced that it will be paying the dividend in kind based on the closing price of its common stock, par value $0.001 per share on September 30, 2024. Holders of record will receive the dividend

      10/1/24 8:31:00 AM ET
      $MGRM
      Medical/Dental Instruments
      Health Care

    $MGRM
    Leadership Updates

    Live Leadership Updates

    See more
    • Monogram Accepted to NVIDIA Inception Program

      Collaboration to Provide Monogram with Technical Resources to Drive Development and Commercialization of mBôs SystemAUSTIN, TX / ACCESSWIRE / April 11, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced it has joined NVIDIA Inception, a program designed to help companies evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA.NVIDIA Inception will help drive Monogram to help drive development of its mBôs robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation co

      4/11/24 1:20:00 PM ET
      $MGRM
      Medical/Dental Instruments
      Health Care